コンテンツへスキップ
Merck
すべての画像(1)

主要文書

すべての文書を表示

安全性情報

890705P

Avanti

16:0-18:1 EPC (Cl Salt)

Avanti Research™ - A Croda Brand 890705P, powder

別名:

1-palmitoyl-2-oleoyl-sn-glycero-3-ethylphosphocholine (chloride salt)

ログイン組織・契約価格を表示する
すべての画像(1)

About This Item

実験式（ヒル表記法）:
C44H87NO8PCl
CAS番号:
328250-19-7
分子量:
824.59
MDL番号:
MFCD22495360
UNSPSCコード:
12352211
NACRES:
NA.25

フォーム

powder

包装

pkg of 1 × 10 mg (890705P-10mg)
pkg of 1 × 25 mg (890705P-25mg)

メーカー／製品名

Avanti Research™ - A Croda Brand 890705P

アプリケーション

advanced drug delivery

脂質タイプ

transfection
cationic lipids

輸送温度

dry ice

保管温度

−20°C

SMILES記法

O=P(OCC[N+](C)(C)C)(OC[C@]([H])(OC(CCCCCCC/C=C\CCCCCCCC)=O)COC(CCCCCCCCCCCCCCC)=O)OCC.[Cl-]

InChI

1S/C44H87NO8P.ClH/c1-7-10-12-14-16-18-20-22-23-25-27-29-31-33-35-37-44(47)53-42(41-52-54(48,50-9-3)51-39-38-45(4,5)6)40-49-43(46)36-34-32-30-28-26-24-21-19-17-15-13-11-8-2;/h22-23,42H,7-21,24-41H2,1-6H3;1H/q+1;/p-1/b23-22-;/t42-,54?;/m1./s1

InChI Key

SXRDCCSKGWBZFF-ISBKSCLYSA-M

詳細

1-palmitoyl-2-oleoyl-sn-glycero-3-ethylphosphocholine (16:0-18:1 EPC) is cationic lipid containing an ethyl group attached to the phosphate moiety through an ester bond and has a choline headgroup.

アプリケーション

1-palmitoyl-2-oleoyl-sn-glycero-3-ethylphosphocholine (chloride salt) (16:0-18:1 EPC (Cl Salt)) might be used:
  • as a cationic lipid to explore the change in organization and dynamics of a membrane-bound fluorescent probe in host membranes of varying charge
  • in the preparation of small unilamellar cationic liposomes
  • in a novel albumin-associated lipoplex formulation to evaluate the antitumoral efficacy of immuno-gene therapy and “suicide” gene therapy

生物化学的／生理学的作用

1-palmitoyl-2-oleoyl-sn-glycero-3-ethylphosphocholine (16:0-18:1 EPC) is a potential transfection agent, which is also similar to the natural lipids.

包装

5 mL Clear Glass Sealed Ampule (890705P-10mg)
5 mL Clear Glass Sealed Ampule (890705P-25mg)

法的情報

Avanti Research is a trademark of Avanti Polar Lipids, LLC

保管分類コード

11 - Combustible Solids

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

890705P-VAR:
890705P-BULK:
890705P-10MG:
890705P-25MG:

最新バージョンのいずれかを選択してください：

試験成績書（COA）

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 資料 section.

サポートが必要な場合は、お問い合わせください カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Marta Passadouro et al.
International journal of nanomedicine, 9, 3203-3217 (2014-07-26)
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and mortal cancer, characterized by a set of known mutations, invasive features, and aberrant microRNA expression that have been associated with hallmark malignant properties of PDAC. The lack of effective PDAC treatment
Wei Zong et al.
Langmuir : the ACS journal of surfaces and colloids, 34(23), 6874-6886 (2018-05-20)
The success of nanoparticulate formulations in drug delivery depends on various aspects including their toxicity, internalization, and intracellular location. Vesicular assemblies consisting of phospholipids and amphiphilic block copolymers are an emerging platform, which combines the benefits from liposomes and polymersomes
Boris G Tenchov et al.
Biochimica et biophysica acta, 1778(10), 2405-2412 (2008-08-30)
Synthetic cationic lipids can be used as DNA carriers and are regarded to be the most promising non-viral gene carriers. For this investigation, six novel phosphatidylcholine (PC) cationic derivatives with various hydrophobic moieties were synthesized and their transfection efficiencies for
Rumiana Koynova et al.
Biochimica et biophysica acta, 1768(2), 375-386 (2006-12-13)
Lipoplexes containing a mixture of cationic phospholipids dioleoylethylphosphatidylcholine (EDOPC) and dilauroylethylphosphatidylcholine (EDLPC) are known to be far more efficient agents in transfection of cultured primary endothelial cells than are lipoplexes containing either lipid alone. The large magnitude of the synergy
Li Wang et al.
Molecular pharmaceutics, 4(4), 615-623 (2007-04-06)
To date, the primary approach to improving the transfection properties of cationic lipids has been the synthesis of new kinds of cationic amphipaths. Recently, however, it was found that combining two cationic lipid derivatives having the same head group but
関連する文献をすべて表示

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら（テクニカルサービス）